ARTICLE | Company News
S*BIO, Tragara deal
January 26, 2009 8:00 AM UTC
S*BIO granted Tragara an exclusive, worldwide license to develop and commercialize SB1317. The oral inhibitor of FMS-like tyrosine kinase 3 ( FLT3) and cyclin dependent kinases (CDKs) is in preclini...